Small Intestine Cancer
85
3
3
67
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Research Maturity
67 completed trials (79% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.9%
5 terminated out of 85 trials
93.1%
+6.5% vs benchmark
6%
5 trials in Phase 3/4
12%
8 of 67 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 67 completed trials
Clinical Trials (85)
Integrated Cancer Repository for Cancer Research
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Target-specific immunoPET Imaging of Digestive System Carcinoma
Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
Project HERO: Health Empowerment & Recovery Outcomes
Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study)
GI Organ Tracking Via Balloon Applicators
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Nutrition in Gastrointestinal Tumors
Programs To Support You During Chemotherapy
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Treatment for Chronic Pain in Patients With Advanced Cancer
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
PreOPerative Imaging of NeuroEndocrine Tumors
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma